Invion

Invion R&D per Employee

The R&D Spending per Employee of Invion (IVX.AX) as of Oct 29, 2026 is 185,355.25 AUD. In the previous year, R&D Spending per Employee was 161,285.63 AUD — a change of 14.92% (higher).

R&D per Employee

185,355.25AUD

YoY

14.92%

Last updated:

R&D Spending per Employee of Invion is 2026 185,355.25 AUD. R&D Spending per Employee of Invion was 2025 161,285.63 AUD. It decreases by 14.92% higher compared to the previous year.

The Invion R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
278,791.63 AUD
Jan 1, 2020
193,912.00 AUD
Jan 1, 2021
189,940.25 AUD
Jan 1, 2022
290,330.63 AUD
Jan 1, 2023
362,276.00 AUD
Jan 1, 2024
336,377.13 AUD
Jan 1, 2025
161,285.63 AUD
Jan 1, 2026
185,355.25 AUD
The Invion R&D per Employee history
YEARR&D per EmployeeYoY
185,355.25AUD+14.92%
161,285.63AUD-52.05%
336,377.13AUD-7.15%
362,276.00AUD+24.78%
290,330.63AUD+52.85%
189,940.25AUD-2.05%
193,912.00AUD-30.45%
278,791.63AUD+513.31%
45,457.00AUD+1,077.30%
3,861.13AUD-97.63%
162,749.00AUD-85.02%
1.09 MAUD+369.49%
231,347.63AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

R&D Spending per Employee of Invion is 185,355.25 AUD in 2026.

R&D Spending per Employee of Invion changed from 161,285.63 AUD to 185,355.25 AUD, representing a 14.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Invion since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Invion

All Key Metrics — Invion